Merck KGaA has raised its full-year outlook for the third time, driven by strong performance in its life science division and better-than-expected results from its multiple sclerosis drug. The company now expects adjusted earnings to reach as much as €6.4 billion ($7.1 billion), up from the previous forecast of €6.3 billion. This revision comes despite the drug facing generic competition.
The increase in guidance also includes higher net sales projections for the year. Merck KGaA attributed the positive outlook to the resilience of its lab-equipment business, which has been a key growth driver. The company announced these updates on Thursday.